FDA Drug Review Office Plans Overhaul To Boost Efficiency
The U.S. Food and Drug Administration's Office of New Drugs has proposed structural changes and reforms designed to improve the efficiency of its drug review process by at least 20 percent,...To view the full article, register now.
Already a subscriber? Click here to view full article